吉西他滨联合顺铂治疗晚期胆系肿瘤的近期疗效和安全性观察  

Efficacy and Safety of Combination Therapy of Gemcitabine and Cisplatin for Advanced Biliary Tract Cancer

作　　者：杨爱荣[1] 

机构地区：[1]青海大学附属医院,青海西宁810001

出　　处：《中国医学创新》2014年第32期106-109,共4页Medical Innovation of China

摘　　要：目的:探讨吉西他滨联合顺铂治疗晚期胆系肿瘤的疗效及相关不良反应。方法:2008年1月-2012年12月本科收治的经病理确诊为晚期胆道系统恶性肿瘤26例,给予吉西他滨1000 mg/m2,静脉滴注,第1、8天;顺铂75 mg/m2,静脉滴注,第1天,每21天为一周期。结果:吉西他滨联合顺铂治疗晚期胆系肿瘤的客观有效率为34.6%(9/26),疾病控制率为73.1%(19/26),其中CR 1例,PR 8例,SD 10例,PD 7例;化疗后主要不良反应为恶心呕吐(21例,80.8%)、白细胞减少(18例,69.2%)、血小板减少(12例,46.2%)、血红蛋白减少(10例,38.5%)、肝功能损害(11例,42.3%)、口腔黏膜炎(8例,30.8%)、肾功能损害(5例,19.2%)、腹泻(5例,19.2%),均在可耐受范围。结论:吉西他滨联合顺铂治疗晚期胆道系统肿瘤有效,不良反应较轻,安全性良好。Objective：To investigate the efficacy and safety of combination therapy of gemcitabine and cisplatin for advanced biliary tract cancer.Method：A total of 26 cases of advanced biliary tract cancer in our hospital from January 2008 to December 2012 accepted combination therapy of gemcitabine（1000 mg/m^2,intravenous infusion 30 min,qd,d1、8） and cisplatin（75 mg/m^2, intravenous infusion,qd,d1） every 21-day cycle. Result：The objective response rate of combination therapy of gemcitabine and cisplatin was 34.6%（9/26）, disease control rate was 73.1%（19/26）, including CR 1 case, PR 8 cases, SD 10 cases, PD 7 cases. The major adverse reactions were nausea and vomiting（80.8%）,leukopenia（69.2%）,thrombocytopenia（46.2%）,hemoglobin decreased（38.5%）, hepatic dysfunction（42.3%）,oral mucositis（30.8%）,renal dysfunction（19.2%）,diarrhea（19.2%）. Conclusion：The combination thrapy regime with gemcitabine and cisplatin is recommended for patients with advanced biliary tract cancer,which is effective and safe.

关 键 词：吉西他滨 顺铂 胆系肿瘤 化疗 

分 类 号：R735.8[医药卫生—肿瘤]